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The efficacy of radiotherapy critically depends on the activation of intrinsic cell death programs in cancer cells. This
implies that evasion of cell death, a hallmark of human cancers, can contribute to radioresistance. Therefore, novel
strategies to reactivate cell death programs in cancer cells are required in order to overcome resistance to radiotherapy.
Since Inhibitor of Apoptosis (IAP) proteins are expressed at high levels in multiple cancers and block cell death induction
at a central point, therapeutic targeting of IAP proteins represents a promising approach to potentiate the efficacy of
radiotherapy. The current review discusses the concept of targeting IAP proteins in combination with radiotherapy.Introduction
The antitumor activity of radiotherapy largely depends on
the activation of a cell-intrinsic program of cell death.
There are several forms of programmed cell death and
apoptosis represents one of the best characterized modes
of programmed cell death that plays an important regula-
tory role during various physiological and pathophysio-
logical processes [1]. Cancer cells are characterized by the
inability to undergo cell death [2]. This evasion of apop-
tosis contributes not only to carcinogenesis and progres-
sion of tumors, but also to resistance to various current
therapies including radiotherapy [3]. This implies that it
will be critical to find new ways to overcome apoptosis re-
sistance in order to improve the efficacy of radiotherapy.
One strategy resides in antagonizing antiapoptotic mecha-
nisms, thereby lowering the threshold for the induction
of radiotherapy-mediated cell death. The current review
focuses on targeting IAP proteins, a family of antiapopto-
tic proteins that play a critical role in the regulation of
sensitivity and resistance of cancer cells.
IAP proteins as therapeutic targets for radiosensitization
The family of IAP proteins comprises eight human mem-
bers among which X-linked Inhibitor of Apoptosis protein
(XIAP) possesses the most pronounced antiapoptotic ac-
tivity via binding to and inhibiting caspase-3, -7 and -9Correspondence: simone.fulda@kgu.de
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unless otherwise stated.[4]. Caspases are a family of proteases that play a critical
role as effector molecules of apoptosis [5]. Upon ac-
tivation, for example via proteolytic cleavage of their pro-
enzyme forms, caspases cleave a large variety of substrates
and effector caspases including caspase-3 and -7 which
are known as central effector molecules of apoptotic cell
death. In addition to blocking caspase activation, IAP pro-
teins can disable the induction of cell death via their Really
Interesting New Gene (RING) domain with E3 ligase ac-
tivity, which is responsible for the ubiquitination and sub-
sequent degradation of apoptosis-regulatory factors by the
proteasome [4]. Also, the E3 ligase activity of IAP pro-
teins, e.g. of XIAP and cellular Inhibitor of Apoptosis
(cIAP) proteins, is involved in the modulation of Nuclear
Factor-kappaB (NF-κB) activation [4]. While cIAP1 and
cIAP2 promote activation of the canonical NF-κB pathway
by non-degradative ubiquitination of the serine/threonine
kinase receptor-interacting protein (RIP)1, they limit non-
canonical NF-κB signaling by mediating the constitutive
proteasomal degradation of NF-κB-inducing kinase (NIK),
a kinase that initiates signaling in the non-canonical
NF-κB cascade. IAP proteins can control cell death sig-
naling pathways via distinct mechanisms, e.g. by inhibiting
caspases, by preventing the assembly of a cytosolic multi-
protein complex that contains, among other proteins,
RIP1 and signals to cell death and by stimulating NF-κB
activation and NF-κB-dependent upregulation of cytotoxic
cytokines [4]. Thus, IAP proteins are not only involved in
the regulation of apoptosis, but also in the control of
necroptosis, an alternative, non-apoptotic form of pro-
grammed cell death [6].an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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since they block cell death pathways at several levels and
are expressed at high levels in various cancers [7]. In
addition, XIAP expression levels have been reported to
be upregulated in response to irradiation, resulting in re-
sistance to radiation-induced cell death [8,9]. Against
the background that IAP proteins are critical regulators
of cell death and survival in cancer cells, the therapeutic
targeting of IAP proteins has attracted considerable at-
tention over the last decades. More specifically, several
approaches have been developed to neutralize IAP pro-
teins in human cancers in order to lower the threshold
for the induction of cell death or to directly engage the
apoptotic program. One of the most promising strategies
has been the development of small-molecule inhibitors
of IAP proteins that mimick the endogenous IAP protein
antagonist second mitochondrial-derived activator of
caspases (Smac), a mitochondrial protein that is released
from the mitochondrial intermembrane space into the
cytosol upon the induction of apoptosis [4]. Smac binds
to and neutralizes IAP proteins including XIAP, cIAP1
and cIAP2. Smac mimetics that neutralize XIAP, ciAP1
and cIAP2, are considered to exert their maximal anti-
tumor activity by targeting XIAP as well as cIAP pro-
teins [10]. The Smac mimetic-mediated neutralization
of XIAP results in increased caspase activation and
caspase-mediated apoptosis, while the inhibition of cIAP
proteins can engage an autocrine/paracrine cell death
loop via Tumor Necrosis factor (TNF)α/TNF receptor
(TNFR)1 signaling. This autocrine TNFα loop is engaged
upon treatment with Smac mimetics via depletion of
cIAP proteins by the proteasome which in turn sti-
mulates non-canonical NF-κB signaling and subsequent
upregulation of NF-κB target genes such as TNFα. Sub-
sequent binding of TNFα to TNFR1 can engage cell
death pathways in the presence of Smac mimetics that
cause depletion of cIAP proteins. Besides this autocrine/
paracrine TNFα loop that signals to cell death, death re-
ceptor 5 (DR5) has been identified as a critical mediator
of Smac mimetic-induced apoptosis [11].
Genetic inhibition of IAP proteins for radiosensitization
Several genetic approaches have been described to neu-
tralize the antiapoptotic function of IAP proteins in order
to enhance the sensitivity of cancer cells for radiotherapy.
One possibility is ectopic expression of Smac. Overexpres-
sion of full-length or the mature form of Smac has been
described to substantially enhance γ-irradiation-mediated
apoptosis of neuroblastoma, glioblastoma or pancreatic
carcinoma cells and also suppressed clonogenic, long-
term survival [12]. Mechanistic studies showed that ec-
topic expression of Smac did not alter the DNA damage/
repair response or activation of cellular stress programs
including NF-κB or activation of DNA damage check-point regulators such as p53 and p21 in response to
γ-irradiation [12]. Instead, overexpression of Smac poten-
tiated the γ-irradiation-stimulated activation of caspases,
loss of mitochondrial membrane potential and cyto-
chrome c release as well as activation of caspases [12].
Similarly, RNA interference-mediated silencing of XIAP
significantly increased γ-irradiation-mediated apoptosis of
pancreatic carcinoma cells [13]. Also in breast carcinoma,
overexpression of full-length or the mature form of Smac
increased the apoptosis-induced potential of irradiation
[14]. Moreover, increased radiosensitivity was reported in
chondrosarcoma cells, laryngeal carcinoma, colorectal
carcinoma or lung carcinoma upon genetic silencing of
XIAP [15-19]. It is interesting to note that the radiation-
mediated apoptosis upon XIAP knockdown was even
more pronounced in mutated p53 lung carcinoma cells
compared to wild-type p53 cells [18], indicating that XIAP
targeting might be especially effective for radiosensitiza-
tion in lung carcinoma cells with mutated p53 [18].
Pharmacological inhibition of IAP proteins for
radiosensitization
In addition to the above mentioned genetic approaches to
neutralize IAP proteins in human cancers in order to
eliminate a key control point in radioresistance, a range of
small-molecule inhibitors of IAP proteins have been de-
veloped over the last years. For example, small-molecule
inhibitors of IAP proteins were reported to significantly
enhance γ-irradiation-mediated apoptosis and loss of via-
bility of glioblastoma cells [20]. In addition, IAP inhibitors
cooperated with γ-irradiation to suppress long-term
clonogenic survival of glioblastoma cells [20]. This
IAP inhibitor-mediated radiosensitization was shown to
involve increased mitochondrial outer membrane per-
meabilization, caspase activation and caspase-mediated
apoptotic cell death [20]. In addition to established glio-
blastoma cell lines, IAP inhibitors were also able to
sensitize primary cultured glioblastoma cells derived from
glioblastoma samples as well as glioblastoma-initiating
stem-like cancer cells for cell death upon γ-irradiation
[20]. In sharp contrast, IAP inhibitors failed to increase
radiotoxicity in several non-malignant cells of the central
nervous system [20]. These results point to some tumor
selectivity of IAP inhibitor-mediated radiosensitization in
glioblastoma. Furthermore, the small-molecule Smac mi-
metic BV6 was shown to be a potent sensitizer of glio-
blastoma cells for γ-irradiation-mediated apoptosis [21].
Interestingly, NF-κB turned out to exert proapoptotic
functions in this model of apoptosis, as it was shown to be
critically required for Smac mimetic-imposed radiosen-
sitization of glioblastoma cells [21]. Genetic inhibition of
NF-κB by overexpression of a dominant-negative superre-
pressor IκBα rescued BV6- and γ-irradiation-mediated
apoptosis underlining that NF-κB is required for cell death
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pression of a kinase dead mutant of IKKβ abolished the
BV6-mediated increased cell death upon γ-irradiation
[21]. The potency of this combination therapy of BV6 and
γ-irradiation was documented by calculation of combin-
ation index (CI) which revealed a high degree of synergy
[21]. The clinical relevance was emphasized by parallel
experiments using primary glioblastoma specimens [21],
showing that BV6 similarly enhanced γ-irradiation-
mediated cell death in primary cultured glioma cells as
well as in glioblastoma-initiating cancer stem cells [21].
Furthermore, the Smac mimetic LBW242 was described
to enhance the cytotoxic activity of radiotherapy of glio-
blastoma cells. In vivo studies in a glioblastoma xenograft
mouse model also showed a synergistic suppression of
tumor growth by co-administration of LBW242 radiation
and Temozolomide (TMZ) [22]. These results demon-
strate that the anti-glioma activity of radiotherapy and
TMZ as state-of-the-art chemotherapy can be potentiated
by the addition of Smac mimetic. Furthermore, small-
molecule inhibitors of IAP proteins were shown to
sensitize pancreatic carcinoma cells for γ-irradiation-
triggered apoptosis [13]. In contrast, these IAP inhibitors
did not affect γ-irradiation-induced apoptotic cell death of
non-malignant fibroblasts, pointing to some tumor selec-
tivity [13]. This potentiation of radiation-induced apoptosis
by IAP inhibition was also documented in an independent
study [23]. Here, the XIAP antagonist compounds 1396-11
and 1396-12 were shown to increase radiosensitivity of
pancreatic carcinoma in vitro and in a subcutaneous xeno-
graft model in vivo [23]. The potential of Smac mimetics to
confer increased radiosensitivity was also documented in a
range of carcinoma types including lung carcinoma, breast
carcinoma, head and neck squamous cell carcinoma, pros-
tate carcinoma and colorectal carcinoma [22,24-27]. In
breast carcinoma, the Smac mimetic SM164-mediated
radiosensitization was shown to involve both extrinsic and
intrinsic apoptosis pathways including activation of
caspases [24]. Mechanistic studies in head and neck squa-
mous cell carcinoma revealed that Smac mimetic SM164-
mediated radiosensitization was linked to NF-κB activation
and secretion of TNFα, followed by activation of caspases
and caspase-mediated apoptosis [25]. The Smac mimetic-
mediated radiosensitization was also confirmed in a tumor
xenograft model of head and neck squamous cell car-
cinoma with minimal toxicity [25]. Similarly, the Smac
mimetic SH130 was shown to potentiate the growth-
inhibitory effects of radiotherapy in a mouse xenograft
model of prostate cancer without increasing systemic
toxicity [26]. In mechanistic terms, it is interesting to note
that the Smac mimetic SH130 was reported to reduce
radiation-mediated activation of NF-κB in prostate carcin-
oma cells, pointing to a context-dependent role of NF-κB
in Smac mimetic-mediated radiosensitization [26]. Besidessmall-molecule inhibitors of IAP proteins, antisense oligo-
nucleotides targeting XIAP were recorded to increase ra-
diosensitivity in preclinical models of lung cancer [28].
XIAP antisense oligonucleotides not only enhanced
irradiation-induced apoptosis in vitro but also potentiated
the growth delay upon irradiation in a xenograft mouse
model in vivo [28].
Conclusions
The concept to neutralize IAP proteins for radiosensitiza-
tion of human cancers has proved to be a promising strat-
egy for radiosensitization of human cancers in various
preclinical models in vitro and in vivo. Since several dis-
tinct Smac mimetics are currently being evaluated in early
clinical trials, both as monotherapy as well as in combin-
ation with other cytotoxic therapies including chemother-
apy, it is feasible that this concept can in principle be
translated into a clinical application. To this end, it will be
important to identify biomarkers that might help to select
those groups of patients that will benefit most from Smac
mimetic-based combination therapies with radiotherapy.
Taken together, targeting IAP proteins, e.g. by small-
molecule inhibitors such as Smac mimetics, represents a
promising avenue for future research in order to enhance
the efficacy of radiotherapy.
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